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CORRECTIONS
CORRECTION
For the article “Long-term results of carotid stenting are competitive with surgery,” published in J Vasc Surg
2005:41;213-21, an incorrect statistical method was used. Please see corrected portions of text from the article below
along with corrected tables.
Structured Abstract
Objective:The feasibility of carotid stenting (CS) is no longer questionable, although its indications remain debatable.
Until the results of randomized trials are available, personal series and registries should help in the comparison of
long-term results of CS with those of endarterectomy. We report here the long-term results of a large series of CS in
our department with a long follow-up. This retrospective study reviews a single surgeon’s 11-year experience with CS.
Our results are compared with those of conventional surgery emanating from our own series and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET), European Carotid Surgery Trial (ECST), and Asymptom-
atic Carotid Atherosclerosis Study (ACAS).
Materials and Methods: CS has been performed in our department in a single, semi-private institution for 12 years.
Patients with high lesions, and postradiotherapy and postendarterectomy stenoses were treated with CS, as were
patients at high risk for surgery. The others were operated on with conventional endarterectomy. During the study,
we performed 221 CS procedures on 193 patients (150 men and 43 women). The average follow-up was 2.7 years
(1 month to 9.3 years). We analyzed the late results in terms of prevention from stroke, the freedom from new
neurologic events, and also patency rates of the treated carotid vessels. We also identified predictors for neurologic
complication and in-stent restenosis by using univariate analysis.
Results:Life-table analyses at 10 years gave a 96% (confidence interval [CI]3%) rate for stroke freedom, a 98% (CI2%)
rate for fatal stroke freedom, and a primary assisted patency rate of 95% (CI 3%). Predictors for neurologic complication
were age 70 (P  .041), and potential renal insufficiency (P  .056). In-stent restenosis occurrence extended from 2
months to 4.5 years after the procedure. The restenosis rates at 6 months, 1, 2, and 4.5 years were, respectively, 1.4%, 2.3%,
3.7%, and 5.9% (13/221). No factors were found to be strong predictors of in-stent restenosis.
Conclusion:These long-term results show that CS is competitive with conventional surgery. A more accurate selection
for CS or surgery might reduce the rate of complications after carotid stenosis repair.
Results heading, page 215, 2nd paragraph
The Fisher test on risk factors and comorbidities showed (Tables I and II) that age 70 years (P  .04) and,
potentially, renal insufficiency (P  .056) were independently associated with higher postoperative neurologic
complications. Amongst features of the lesion (Tables I and II), the etiology of the lesions and their symptomatology
were not significant (P  .993 and P  .281). Amongst technical factors (Tables I and II), the type of cerebral
protection systems showed no incidence on neurologic complications (P .478), and predilation was not significant
(P .549). The femoral route rather than the cervical one showed a 5 fold increase in neurological complication rate
although the difference was not significant (P  .351).
Results heading, Subheading: In-stent restenosis, page 216
In-stent restenosis.As defined previously, the restenosis rates at 6 months, 1 year, and 2 years were 1.36%, 1.8%, and
3.2%, respectively. The overall late restenosis rate in our series was 6.8%. We observed 15 ISR in 13 patients. One
patient had a delayed bilateral ISR and another had two ISR on two homolateral stents at the right carotid bifurcation
and the distal right internal carotid artery.
None of the different factors tested showed any independent predictor of ISR with the Fisher test (Tables III and IV).
Results heading, Subheading: Freedom from stroke, 3rd paragraph, page 217
We found in this study that renal insufficiency and age 70 years, and a lesion located at the bifurcation were good
predictors of early and late neurologic complications of CS. Other studies identified old age,29 preoperative
symptoms,27 length of the lesion,27 and echogenicity of the plaque31 as predictors for early new neurologic events.
Discussion heading, Subheading: The fate of stents, pages 217 and 218.
Concerning the fate of stents, Criado et al32 reported an ISR rate of 3%, Henry et al33 of 4.7%, Roubin et al29 6% for
BE stents and 8% for SE stents at 3 years and Chakhtoura et al34 8%. These ISR rates on de novo lesions are similar
to and can compete with restenosis after endarterectomy, ranging from 4 to 22% for hemodynamic restenosis.35-38
Only one report28 related a higher restenosis rate in patients treated by CAS, with a freedom from restenosis 50%
at 3 years of only 44%. However this result relies only on 13 patients.871
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predicting ISR have been identified23; in our experience, we found no significant predictor of ISR. Wholey and
colleagues39 reported recently a vessel patency (ISR 50%) at 3 years of 96.3% for BE stents and 83.7% for SE stents. Our
results may be due to the longer follow-up period we have on BE stents compared to SE stents. The influence of the type
of stent will be investigated in future works. More often, carotid stenting appears to heal the atheromatous plaque, with a
thin endothelial layer. Other works are reporting that post-endarterectomy stenosis is a predictive factor of ISR.40
Table I. Results of the Fisher’s test for risk factors, lesion features and technical factors on neurological
complications after CS. This table shows the number of cases, the global number of patients in each group and
the P value as a result of the Fisher’s test.
Type of predictive
factor
Complications No complication
Total number Nb with factor %
(2/1)
Total number Nb with factor %
(4/3) P value(1) (2) (3) (4)
Risk factor (a)
Renal
insufficiency
36 3 8.33 185 3 1.62 0.056
Male sex 36 31 86.11 185 141 76.21 0.272
Age  70 36 27 75 185 104 56.21 0.041
Lesion factor (b)
Lesion at the
bifurcation
36 9 25 185 27 14.59 0.149
Technical factors (c)
Femoral access
site
36 17 47.22 185 19 10.27 0.351
Protected CS 36 20 55.56 185 75 40.54 0.102
Self-expandable
stents
36 2 5.56 185 66 35.67 0.236
Table II. Results of the Fisher’s test for risk factors, lesion features and technical factors on neurological
complications after CS. This table shows the percentage of factors in each group of patients, the increase in
percentage between the group with complications compared to the group with no complication, and the P value.
Type of predictive
factor
% with factor amongst
complications
% with factor amongst
no complication
Increase in
complication risk P value
Risk factors
Renal insufficiency 7.50 1.62 4.63 0.056
Male sex 92.50 76.21 1.21 0.272
Age  70 73.17 56.21 1.30 0.041
Lesion factor
Lesion at the bifurcation 26.83 14.59 1.84 0.149
Technical factors
Femoral access site 53.66 10.27 5.22 0.351
Protected CS 53.66 40.54 1.32 0.102
Self-expandable stents 5.56 35.67 0.15 0.236
Table III. Results of the Fisher’s test for lesion features and technical factors on ISR after CS. This table shows
the number of cases, the global number of patients in each group and the P value as a results of the Fisher’s test
Type of predictive
factors Factors
ISR Free from ISR
P value
Total number
Nb with risk
factor %
(2/1)
Total number
Nb with risk
factor %
(4/3)(1) (2) (3) (4)
Lesion factor Asymptomatic lesions 13 11 84.61 208 125 60.09 0.514
Technical factor Balloon expandable stent 13 11 84.61 203 137 67.48 0.669
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the percentage of factors in each group of patients, the increase in percentage between the group with
complications compared to the group with no complication, and the P value.
Type of predictive
factors Factors
% with factor
amongst ISR
% with factor amongst
free from ISR Increase in ISR risk P value
Lesion factor Asymptomatic lesions 84.61 60.09 1.41 0.514
Technical factor Balloon expandable stent 84.61 67.48 1.25 0.669
